F. Giles, G. Garcia-Manero, J. Cortes
2002
Citations
0
Influential Citations
24
Citations
Quality indicators
Journal
Haematologica
Abstract
Ursodiol is variably reported to reduce stem cell transplantation (SCT)-associated hepatic venoocclusive disease (VOD). VOD developed in 10 of 85 (12%) patients receiving Mylotarg-based regimens with ursodiol 300 mg bid for 21 days beginning on the day prior to cytotoxic therapy - an incidence seen with these regimens when administered without ursodiol.